Houston received a major boost in its fight against cancer as local hospitals, startups, and community programs secured significant state-backed funding to support clinical trials, diagnostic tools, prevention outreach, and recruitment of top scientists. The Cancer Prevention and Research Institute of Texas approved 73 grants totaling nearly $154 million, bringing the agency’s lifetime investments past $4 billion.
"Today marks an important milestone for CPRIT and for every Texan affected by cancer," CEO Kristen Doyle said, as reported by CPRIT. The funding aims to accelerate cancer research, screenings, and clinical trials across Texas while creating more research jobs in the Texas Medical Center and nearby innovation hubs.
Locally, the Greater Houston Partnership reports that more than $120 million from this round was steered to Houston organizations and companies. Area institutions and researchers pulled in roughly $57.9 million, while eight Houston companies landed about $62.9 million for product development, according to the Partnership's tally. The haul follows a 2024 round that also sent major CPRIT dollars Houston's way and underscores the city's growing clout in cancer commercialization. The Partnership's breakdown highlights a mix of recruitment, prevention and device- and drug-development awards concentrated in and around the Texas Medical Center.
Which Houston Projects Won Big
According to CPRIT, the round included several headline-grabbing awards for Houston firms and labs. CrossBridge Bio secured a roughly $15 million product-development grant to advance a next-generation antibody-drug conjugate. OncoMAGNETx picked up almost $14 million for a device-focused project built around a wearable magnetic-field therapy for brain cancers. ImmunoGenesis was awarded about $10.8 million to push its IMGS-001 program into later-stage testing, and Diakonos Oncology received more than $7 million to advance DOC1021 into a planned phase 1/2 study, among others.
The same vote also approved recruitment grants aimed at pulling senior investigators into Houston labs, including a $5 million CPRIT Scholar recruitment for Baylor College of Medicine and a $3 million recruitment award for MD Anderson. The hires are expected to bolster local research horsepower and help keep high-impact projects anchored in the region.
What Local Leaders Say And What Comes Next
Company leaders and researchers said the money should help fast-track clinical testing and scale up manufacturing for some of the most promising therapies in their pipelines. Diakonos, which presented Phase I DOC1021 results this year and closed private financing, has said the award will speed its planned studies and manufacturing, according to a company press release. ImmunoGenesis, which has presented updates on IMGS-001 at major conferences, has emphasized that larger product-development awards help bridge early clinical proof-of-concept to larger trials. Startup executives added that CPRIT's non-dilutive support often serves as a key signal for private investors and potential strategic partners.
CPRIT funding decisions are approvals to negotiate contracts, so recipients typically move into detailed contracting and program start-up over the following months. Local leaders said they expect to see trial sites launch, device-validation work kick off and recruitment efforts intensify through 2026 as the awards translate into new hires, equipment purchases and clinical activity. The grants build on Houston's momentum as a national cancer-research hub and give local companies and clinics fresh runway to push new treatments closer to patients.
